MedTrace Logo

Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations

NCT00334711 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2006-11-29

No results posted yet for this study

Summary

The purpose of this study is to investigate whether patients with diabetes due to Kir6.2 mutations can be treated with sulfonylurea medication rather than insulin, and if this is the case to investigate the mechanism for sulfonylurea response.

Conditions

Interventions

DRUG

Sulfonylurea

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Hôpital Necker-Enfants Malades

    collaborator OTHER

  • Haukeland University Hospital

    collaborator OTHER

  • Royal Devon and Exeter NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Andrew T Hattersley · Peninsula Medical School, Exeter, UK

  • Ewan R Pearson · Peninsula Medical School, Exeter, UK

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2006-01-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00334711 on ClinicalTrials.gov